drugset / Trial / NCT05288777
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
Non-randomizedParallel-groupSingle-blindTreatment
Summary
The goal of this study is to evaluate the safety and effectiveness of adjuvant chemoradiation therapy in high-risk breast cancer patients who had received neoadjuvant chemotherapy before their lumpectomy and/or mastectomy and were found to have residual disease. As well as examine the effects of this treatment combination on the immune system.
Timeline
- Start
- 2022-07-11
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |